NGS-Based RNA-Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Services (RNA Sequencing Platforms and Consumables, Sample Preparation Products, RNA Sequencing Services, Data Analysis, Storage and Management), By Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing), By Application (Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling and Transcriptome Epigenetics), By End User (Research and Academia, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.18 Billion
CAGR (2026-2031)	6.92%
Fastest Growing Segment	Nanopore Sequencing
Largest Market	North America
Market Size (2031)	USD 4.75 Billion

Market Overview

The Global NGS-Based RNA-Sequencing Market will grow from USD 3.18 Billion in 2025 to USD 4.75 Billion by 2031 at a 6.92% CAGR. NGS-based RNA sequencing is a high-throughput genomic technology utilized to examine the transcriptome, allowing for the precise quantification of gene expression and the detection of novel RNA variants. The market is primarily driven by the accelerating shift toward personalized medicine and the critical need for transcriptomic data in drug discovery, particularly for oncology and rare diseases. This demand is further amplified by the robust development of advanced therapeutics that require rigorous genomic validation. According to the Pharmaceutical Research and Manufacturers of America, in 2024, the industry pipeline included 289 novel cell and gene therapies in development, underscoring the expanding reliance on advanced sequencing tools within the biopharmaceutical sector.

Despite these drivers, the market faces a significant challenge regarding data management and bioinformatics analysis. The massive datasets generated by modern sequencing platforms require substantial computational infrastructure and specialized expertise for accurate interpretation. This computational bottleneck often delays time-to-result and increases operational costs, which can impede broader adoption in clinical settings where rapid and streamlined diagnostics are essential.

Key Market Drivers

The surge in demand for single-cell RNA sequencing represents a primary growth catalyst as researchers increasingly require granular resolution to understand cellular heterogeneity. Unlike bulk sequencing, which averages gene expression across a sample, single-cell platforms allow for the distinct profiling of individual cells, a capability that is crucial for mapping complex tissue microenvironments in oncology and immunology. This technological shift is evidenced by the commercial performance of specialized technology providers. According to 10x Genomics, February 2024, in the 'Full Year 2023 Financial Results' report, the company generated revenue of $618.7 million, a 20% increase over the previous year, driven significantly by the adoption of their spatial and single-cell transcriptomics solutions. This adoption trajectory indicates a fundamental transition in experimental design toward high-resolution modalities that provide deeper biological insights.

Growing investments and funding for genomic research further sustain market expansion by providing the necessary capital for large-scale transcriptomics initiatives and infrastructure upgrades. Public and private entities are channeling substantial resources into establishing advanced data centers and sequencing facilities to accelerate drug discovery pipelines. For instance, according to the Novo Nordisk Foundation, March 2024, in the 'Gefion: New AI supercomputer in Denmark' announcement, the foundation committed approximately DKK 600 million to establish a supercomputer specifically designed to handle massive genomic datasets and accelerate innovation in life sciences. Such funding directly lowers entry barriers for institutions seeking to implement next-generation sequencing workflows. This financial support correlates with the uptake of high-throughput instrumentation; according to Illumina, February 2024, in the 'Fourth Quarter and Fiscal Year 2023 Results' press release, the company confirmed the shipment of 352 NovaSeq X instruments during the fiscal year, underscoring the physical expansion of sequencing capacity globally.

Download Free Sample Report

Key Market Challenges

The Global NGS-Based RNA-Sequencing Market faces a substantial obstacle regarding data management and bioinformatics analysis. As sequencing technologies generate exponentially larger datasets, the capacity to efficiently store, process, and interpret this information has not kept pace, creating a severe computational bottleneck. This disparity complicates the workflow and significantly increases operational costs, often extending the time required to derive actionable insights from raw transcriptomic data. Consequently, the high complexity of managing these massive datasets limits the scalability of RNA sequencing in routine clinical diagnostics, where rapid turnaround times are essential for patient care.

This operational inefficiency directly impacts the market's ability to support drug discovery and precision medicine. According to the Pistoia Alliance, in 2024, 52% of life science R&D professionals identified low-quality and poorly curated datasets as the primary barrier to the effective implementation of advanced analytical tools. This statistic highlights a critical gap in data readiness that hampers the industry's ability to utilize genomic data for rigorous validation. Without streamlined bioinformatics infrastructures, the translation of transcriptomic discoveries into therapeutic applications remains inefficient, thereby restricting the broader expansion of the market.

Key Market Trends

The integration of Artificial Intelligence (AI) and Machine Learning (ML) is fundamentally reshaping transcriptomic data interpretation, addressing the critical bioinformatics bottleneck in high-throughput workflows. By leveraging advanced algorithms, researchers can rapidly deconvolve massive datasets to identify actionable biomarkers and predict therapeutic responses efficiently. This technological synergy is driving market adoption as diagnostic providers embed these tools into core offerings to enhance precision medicine capabilities. According to Tempus AI, February 2025, in the 'Fourth Quarter and Full Year 2024 Results' report, the company recorded a 30.4% year-over-year revenue increase to $693.4 million, attributed to the expansion of its AI-enabled genomics platform.

Simultaneously, the commercialization of third-generation direct RNA sequencing is enabling the detection of native RNA modifications without cDNA conversion bias. These long-read platforms allow for real-time analysis of full-length transcripts, revealing splice variants and methylation patterns that short-read technologies often miss. This capability is expanding into clinical markets, validating the utility of direct sequencing for complex biological applications. According to Oxford Nanopore Technologies, March 2025, in the 'Annual Results for the Year Ended 31 December 2024' announcement, the company achieved an 11% revenue growth at constant currency, driven notably by a 12% expansion in its Clinical segment.

Segmental Insights

Based on current market intelligence, the Nanopore Sequencing segment is identified as the fastest-growing category within the Global NGS-Based RNA-Sequencing Market. This accelerated expansion is primarily attributed to the technology's distinct ability to sequence native RNA strands directly, effectively eliminating the need for amplification or conversion to DNA. By preserving the original genetic modifications and structural integrity of the sample, this method offers superior accuracy for complex transcriptomic studies compared to traditional short-read alternatives. Furthermore, the portability and real-time data processing capabilities of these devices are driving their increased adoption among research institutions for time-sensitive applications such as infectious disease surveillance.

Regional Insights

North America maintains a dominant share of the Global NGS-Based RNA-Sequencing Market due to substantial investment in genomic research and the presence of major biotechnology corporations. The region benefits from strong institutional support, specifically through funding from the National Institutes of Health, which accelerates the development of genomic applications. Furthermore, the established healthcare infrastructure facilitates the rapid adoption of precision medicine, integrating RNA sequencing into standard clinical workflows. This alignment of government initiatives, academic research, and industrial capabilities reinforces the region's leading status in the global market.

Recent Developments

• In October 2025, Twist Bioscience and Element Biosciences expanded their strategic collaboration with the commercial launch of the Trinity Freestyle Sequencing Workflow for the AVITI system. This innovative solution integrated hybridization-based target enrichment directly onto the sequencing flow cell, eliminating the need for traditional wash and amplification steps. The workflow was designed to be compatible with various next-generation sequencing libraries, including those utilized for RNA exome and transcriptome analysis, thereby reducing hands-on time and operational costs. This partnership highlighted a shared commitment to improving the efficiency and scalability of genomic workflows for researchers in the life sciences sector.
• In July 2025, Qiagen announced the launch of its QIAseq xHYB Long Read Panels, a new portfolio of target enrichment solutions tailored for native long-read sequencing platforms. These panels were optimized to work with technologies from partners like Pacific Biosciences, enabling the comprehensive analysis of complex genomic regions and full-length transcriptomes. By facilitating the detection of structural variants and isoforms that are challenging for short-read methods, this launch strengthened the company's position in the next-generation sequencing market. The solution aimed to accelerate translational research by providing more complete genomic and transcriptomic insights for clinical and academic applications.
• In October 2024, 10x Genomics introduced the GEM-X Flex and GEM-X Universal Multiplex products to expand the capabilities of its Chromium single-cell platform. These new offerings were developed to lower the cost per cell and increase sample throughput, effectively democratizing access to large-scale single-cell RNA sequencing studies. The GEM-X technology architecture provided improved sensitivity and cell capture efficiency, allowing researchers to detect a higher number of genes and analyze complex biological systems with greater resolution. This product launch underscored the company's strategy to support high-throughput transcriptomic applications in critical research areas such as oncology and immunology.
• In March 2024, Oxford Nanopore Technologies launched an upgraded version of its Direct RNA Sequencing Kit, designed to sequence native RNA strands without the need for reverse transcription or amplification. This release featured improved chemistry and updated basecalling algorithms that significantly enhanced raw read accuracy and increased data output per flow cell. The advancement allowed for the precise detection of RNA modifications, such as N6-methyladenosine, and the identification of full-length transcript isoforms in a single assay. By preserving the native state of the molecule, the kit provided researchers in the global NGS-based RNA-sequencing market with a powerful tool for investigating the epitranscriptome and gene expression regulation.

Key Market Players

• Illumina Inc.
• Thermo Fischer Scientific Inc.
• Oxford Nanopore Technologies plc
• Agilent Technologies, Inc.
• PerkinElmer Inc
• QIAGEN N.V.
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd
• Takara Bio Inc.
• Azenta Life Sciences

By Product and Services	By Technology	By Application	By End User	By Region
RNA Sequencing Platforms and Consumables Sample Preparation Products RNA Sequencing Services Data Analysis Storage and Management	Sequencing	Expression Profiling Analysis Small RNA Sequencing De Novo Transcriptome Assembly Variant Calling and Transcriptome Epigenetics	Research and Academia Hospitals and Clinics Pharmaceutical and Biotechnology Companies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global NGS-Based RNA-Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• NGS-Based RNA-Sequencing Market, By Product and Services:

• RNA Sequencing Platforms and Consumables
• Sample Preparation Products
• RNA Sequencing Services
• Data Analysis
• Storage and Management

• NGS-Based RNA-Sequencing Market, By Technology:

• Sequencing

• NGS-Based RNA-Sequencing Market, By Application:

• Expression Profiling Analysis
• Small RNA Sequencing
• De Novo Transcriptome Assembly
• Variant Calling and Transcriptome Epigenetics

• NGS-Based RNA-Sequencing Market, By End User:

• Research and Academia
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

• NGS-Based RNA-Sequencing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE